Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics
| Autor: | N. Diamantas, I. Gavriil, I. Leontopoulos, S. Tsitouridis, H. Frangos, N. P. Zissis, K. Tsolis |
|---|---|
| Rok vydání: | 1978 |
| Předmět: |
Adult
Male Sleep Wake Disorders medicine.medical_specialty medicine.medical_treatment Fluspirilene Double blind Double-Blind Method Chronic schizophrenics Internal medicine Tremor Fluphenazine medicine Humans Fluphenazine Decanoate Spiro Compounds Parkinson Disease Secondary Psychiatry Antipsychotic Clinical Trials as Topic Parkinsonism Middle Aged Therapeutic evaluation medicine.disease Psychiatry and Mental health Schizophrenia Drug Evaluation Female Psychology medicine.drug |
| Zdroj: | Acta Psychiatrica Scandinavica. 57:436-446 |
| ISSN: | 1600-0447 0001-690X |
| DOI: | 10.1111/j.1600-0447.1978.tb06912.x |
| Popis: | Fifty chronic schizophrenics were randomly assigned to a 16-week treatment either with fluspirilene or with fluphenazine decanoate. The aim of the study was to compare the antipsychotic action and the side effects of the two neuroleptics. Fluphenazine decanoate caused more side effects and the difference between the two groups was statistically significant in the items tremor, severe extrapyramidal effects and parkinsonism. More patients in the fluspirilene group (nine patients) compared with only three in the fluphenazine decanoate group remained free of side effects during the whole trial. Judged from the BPRS fluspirilene proved an equally potent neuroleptic with fluphenazine decanoate although statistically significant improvement has been obtained in more items of the scale in the fluspirilene group. The improvement in the NOSIE-30 was much more clear in the fluspirilene group. Although Clinical Global Impressions of the investigators and the nursing personnel favored fluspirilene, the differences between the two groups were not statistically significant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text